(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the Bio Investor Forum on Wednesday October 19th, at 10:00 AM (Pacific) in conference room Elizabethan B at the Westin St. Francis Hotel, San Francisco, CA.
- 0 Comments
- FY2017